Cargando…
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Multiple myeloma (MM) survival rates have been substantially increased thanks to novel agents that have improved survival outcomes and shown better tolerability than treatments of earlier years. These new agents include immunomodulating imide drugs (IMiD) thalidomide and lenalidomide, the proteasome...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464555/ https://www.ncbi.nlm.nih.gov/pubmed/33990881 http://dx.doi.org/10.1007/s00520-021-06266-x |